Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

New Drug Combinations Block Kidney Cancer in Culture and Mouse Models

By BiotechDaily International staff writers
Posted on 20 May 2013
Print article
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Drugs that block the activity of the enzyme Stearoyl-CoA desaturase-1 (SCD1) repress the growth of kidney cancer cells in culture and in mouse models of the disease.

SCD1, which is overexpressed in most kidney cancer samples, is a key enzyme in fatty acid metabolism responsible for forming a double bond in Stearoyl-CoA. This is the way that the monounsaturated fatty acid oleic acid is produced from the saturated fatty acid stearic acid. The ratio of stearic acid to oleic acid has been implicated in the regulation of cell growth and differentiation through effects on cell membrane fluidity and signal transduction.

Investigators at the Mayo Clinic (Jacksonville, FL, USA) worked with a drug that had been designed to block the activity of SCD1 in clear cell renal cell carcinoma (ccRCC), which accounts for almost 85% of kidney cancer cases in the United States.

The investigators examined patient normal and ccRCC tissue samples and cell lines for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through the use of the drug A939572 were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Models of combined therapy using A939572 and the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus were evaluated.

Results published in the May 1, 2013, issue of the journal Clinical Cancer Research revealed increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or genetic SCD1 knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, which suggested a mechanistic mechanism for SCD1 activity in ccRCC. Furthermore, application of A939572 (25% inhibition when applied alone) combined with temsirolimus inhibited tumor growth by 60%–70% in vitro and in vivo.

“There is a clear need for new therapies for this common cancer. With very few exceptions, patients inevitably become resistant to all available treatments,” said senior author Dr. John Copland, professor of cancer biology at the Mayo Clinic.

“We found it [A939572] to be incredibly specific to cancer cells in laboratory mice treated with the agent,” said Dr. Copland. “But these are early days in the testing of this agent for cancer. The synergy between the drugs [A939572 and temsirolimus] was very striking, suggestive of significant clinical benefit in patients.”

Related Links:
Mayo Clinic



Print article

Channels

Genomics/Proteomics

view channel
Image: The green-labeled cells show a basal cell carcinoma in mouse tail epidermis derived from a single mutant stem cell and expanding out of the normal epidermis stained in red (Photo courtesy of Adriana Sánchez-Danés, Université Libre de Bruxelles).

Stem Cells Not Progenitors Can Trigger Skin Cancer Growth

Cancer researchers have discovered that stem cells can initiate development of malignant skin tumors, while progenitor cells are limited to triggering only benign growths. A progenitor cell is similar... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Sartorius Acquires US Start-up ViroCyt

Sartorius AG (Göttingen, Germany), a pharmaceutical and laboratory equipment provider, has acquired ViroCyt Incorporated (Broomfield, CO, USA), a start-up in the field of rapid virus quantification, in a deal valued at approximately USD 16 million. ViroCyt’s automated platform integrates instruments, software and reagents... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.